Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
Exp3VFjhHv9gr1m3
Listen
